Sihuan-led consortium loses bidding war for Hugel despite higher offer Seller apparently conscious of regulatory vigilance around technology transfer
Translated by Ryu Ho-joung 공개 2021-08-30 07:35:43
이 기사는 2021년 08월 27일 07:55 thebell 에 표출된 기사입니다.
A consortium led by China’s Sihuan Pharmaceutical has lost the bidding war for botox maker Hugel even after offering a higher bid than what a rival consortium led by South Korea’s GS Holdings offered, seemingly due to concerns about technology transfer controls.The GS consortium Tuesday agreed to acquire a controlling stake and convertible bonds in the South Korea-based pharmaceutical company from US private equity firm Bain Capital in a deal worth about 1.7 trillion won ($1.5 billion). The consortium includes GS Holdings – GS Group’s holding company – Seoul-based private equity firm IMM Investment, Singapore-based investment firm CBC Group and Abu Dhabi sovereign fund Mubadala.
The GS consortium beat out a bidder group consisting of Sihuan Pharmaceutical, Goldman Sachs Asset Management and Baring Private Equity Asia.
The Sihuan-led consortium made an offer late in the bidding process. Its offer was reportedly about 10% higher than what the GS consortium offered, which made the seller take more time to evaluate offers both from financial and non-financial perspectives.
The GS consortium was ultimately named as the winner, probably because the seller did not want to take a risk of the deal being stopped by regulatory hurdles, industry watchers said.
“Apparently the fact that Sihuan Pharmaceutical, a Chinese pharmaceutical company, is included in the consortium troubled the seller because of tightened regulations on technology transfer,” said an industry insider.
Botulinum toxin, used to make botox for aesthetic and medical purposes, is also one of the agents that can be used to make biological weapons because of its potent toxicity. Any acquisition by a foreign buyer of shares in a company that owns botulinum toxin technology needs to follow reporting requirements mandated by the South Korean government.
Although the GS consortium’s special purpose vehicle is based in the Cayman Islands, the investor group is led by GS Holdings and IMM Investment, both of which are based in South Korea. In contrast, the Sihuan-led consortium consists entirely of foreign firms.
“If the Sihuan-led consortium was selected, that would attract more scrutiny from regulatory authorities, which could increase uncertainty of the deal closing. This is probably the situation that the seller wanted to avoid,” another industry insider said. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감